The combination of tumor necrosis factor α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model

Arthritis and Rheumatism

Volumn 44, Issue 6, 2001, Pages 1293-1303

  Chabaud, Martine ^a   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM;

ADULT; AGED; ANIMALS; BONE AND BONES; BONE RESORPTION; CELLS, CULTURED; COLLAGEN; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MICE; MIDDLE AGED; SYNOVIAL MEMBRANE; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034966563     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T     Document Type: Article

References (38)

1. 2 release from cartilage in organ culture
2. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
3. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: Effect of in situ blocking in murine antigen- and zymosan-induced arthritis
4. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
5. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
6. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
7. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
8. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
9. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines
10. A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
11. IL-17 enhances the effects of IL-1 on IL-6 and LIF production by rheumatoid arthritis synoviocytes
12. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells
13. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB
14. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
15. Interleukin-17: A new bone acting cytokine in vitro
16. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages
17. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells
18. Combining anti-IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone
19. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer
20. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
21. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
22. Independent binding of interleukin-1a and interleukin-1b to type I and type II interleukin-1 receptors
23. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
24. Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis
25. Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples
26. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
27. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis
28. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
29. Clinical improvement and radiological deterioration in rheumatoid arthritis: Evidence that the pathogenesis of synovial inflammation and articular erosion may differ
30. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis
31. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
32. Flare-up of experimental arthritis in mice with murine recombinant IL-1
33. Effects of interleukin-1 on bone turnover in normal mice
34. Lessons for joint destruction from animal models
35. Effects of murine recombinant interleukin-1 on synovial joints in mice: Measurement of patellar cartilage metabolism and joint inflammation
36. IL-1ab blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-a blockade only ameliorates joint inflammation
37. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro
38. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period